Rationale and design of a randomised phase II multicentre crossover trial investigating a sodium-glucose co-transporter 2 inhibitor, dapagliflozin, combined with a novel continuous ketone monitor in adults with type 1 diabetes to reduce the risk of diabetic ketoacidosis: the PARTNER study

Rationale and design of a randomised phase II multicentre crossover trial investigating a sodium-glucose co-transporter 2 inhibitor, dapagliflozin, combined with a novel continuous ketone monitor in adults with type 1 diabetes to reduce the risk of diabetic ketoacidosis: the PARTNER study

Introduction Sodium-glucose co-transporter inhibitors have potential glycaemic and non-glycaemic benefits in people with type 1 diabetes (T1D). However, the increased risk of diabetic ketoacidosis (DKA) limits their widespread use. We hypothesise that dapagliflozin 10 mg daily, combined with the use...

Full description

Saved in:
Bibliographic Details
Main Authors: Yee Wen Kong, Sara Vogrin, Elif Ekinci, Pamela Taylor, David Norman O’Neal, Alicia Jenkins, Stephen N Stranks, Steven Trawley, Christopher J Nolan, Lynelle Boisseau, Jennifer Ngan, Jenna Goad, Michael L H Huang, Adele Manzoney, Miyuki Nakano, Adamandia Kriketos, Spiros Fourlanos, Joanne Fenn
Format: Article
Language:English
Published: BMJ Publishing Group 2025-05-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/15/5/e098457.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://bmjopen.bmj.com/content/15/5/e098457.full

Similar Items